CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS TREATED WITH TRIAZOFURIN

这是一项II期研究，旨在评估新的抗白血病药物 药物，硫唑福林，诱导血液学缓解患者， 慢性粒细胞白血病急变期的关系 将检查生化和血液学影响，并检查毒性 将对Profile进行评估。我们将研究生物化学与 将对每日血液样本和每周骨髓样本进行参数评估 吸气。随后的整合周期将管理到 回应患者

This is a phase II study to evaluation the capacity of new antileukemic agent, tiazofurin, to induce hematologic remissions in patients with chronic myelogenous leukemia in blast crisis. The relationship between the biochemical and hematologic effects will be examined and the toxicity profile will be assessed. We will examine relationship between biochemical parameters will be assessed on daily blood samples and weekly bone marrow aspirates. Subsequent consolidation cycles will be administered to responding patients.